These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33809310)

  • 1. [
    Lu Y; Li M; Massicano AVF; Song PN; Mansur A; Heinzman KA; Larimer BM; Lapi SE; Sorace AG
    Molecules; 2021 Mar; 26(6):. PubMed ID: 33809310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging of HER2 with [
    Massicano AVF; Lee S; Crenshaw BK; Aweda TA; El Sayed R; Super I; Bose R; Marquez-Nostra BV; Lapi SE
    Cancer Biother Radiopharm; 2019 May; 34(4):209-217. PubMed ID: 30676778
    [No Abstract]   [Full Text] [Related]  

  • 3. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with
    McKnight BN; Viola-Villegas NT
    Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts.
    Marquez BV; Ikotun OF; Zheleznyak A; Wright B; Hari-Raj A; Pierce RA; Lapi SE
    Mol Pharm; 2014 Nov; 11(11):3988-95. PubMed ID: 25058168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using
    Ulaner GA; Lyashchenko SK; Riedl C; Ruan S; Zanzonico PB; Lake D; Jhaveri K; Zeglis B; Lewis JS; O'Donoghue JA
    J Nucl Med; 2018 Jun; 59(6):900-906. PubMed ID: 29146695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and
    Vivier D; Fung K; Rodriguez C; Adumeau P; Ulaner GA; Lewis JS; Sharma SK; Zeglis BM
    Theranostics; 2020; 10(4):1746-1757. PubMed ID: 32042334
    [No Abstract]   [Full Text] [Related]  

  • 8.
    Pool M; Kol A; de Jong S; de Vries EGE; Lub-de Hooge MN; Terwisscha van Scheltinga AGT
    MAbs; 2017; 9(8):1370-1378. PubMed ID: 28873009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted
    Ulaner GA; Carrasquillo JA; Riedl CC; Yeh R; Hatzoglou V; Ross DS; Jhaveri K; Chandarlapaty S; Hyman DM; Zeglis BM; Lyashchenko SK; Lewis JS
    Radiology; 2020 Aug; 296(2):370-378. PubMed ID: 32515679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.
    Shah C; Miller TW; Wyatt SK; McKinley ET; Olivares MG; Sanchez V; Nolting DD; Buck JR; Zhao P; Ansari MS; Baldwin RM; Gore JC; Schiff R; Arteaga CL; Manning HC
    Clin Cancer Res; 2009 Jul; 15(14):4712-21. PubMed ID: 19584166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
    McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
    J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor uptake and tumor/blood ratios for [
    Al-Saden N; Cai Z; Reilly RM
    Nucl Med Biol; 2018 Dec; 67():43-51. PubMed ID: 30390575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive
    Henry KE; Dilling TR; Abdel-Atti D; Edwards KJ; Evans MJ; Lewis JS
    J Nucl Med; 2018 Jan; 59(1):51-57. PubMed ID: 28848040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
    Gebhart G; Gámez C; Holmes E; Robles J; Garcia C; Cortés M; de Azambuja E; Fauria K; Van Dooren V; Aktan G; Coccia-Portugal MA; Kim SB; Vuylsteke P; Cure H; Eidtmann H; Baselga J; Piccart M; Flamen P; Di Cosimo S
    J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.
    Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS
    Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological and molecular predictors of [
    Llombart-Cussac A; Prat A; Pérez-García JM; Mateos J; Pascual T; Escrivà-de-Romani S; Stradella A; Ruiz-Borrego M; de Las Heras BB; Keyaerts M; Galvan P; Brasó-Maristany F; García-Mosquera JJ; Guiot T; Gion M; Sampayo-Cordero M; Di Cosimo S; Pérez-Escuredo J; de Frutos MA; Cortés J; Gebhart G
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2733-2743. PubMed ID: 38587643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined
    Wu J; Zhang X; Jia Z; Zhou X; Qi R; Ji H; Sun J; Sun C; Teng Z; Lu G; Chen X
    Mol Pharm; 2022 Sep; 19(9):3405-3411. PubMed ID: 35972444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules.
    Kramer-Marek G; Kiesewetter DO; Capala J
    J Nucl Med; 2009 Jul; 50(7):1131-9. PubMed ID: 19525458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [(89)Zr]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model.
    Wimana Z; Gebhart G; Guiot T; Vanderlinden B; Morandini R; Doumont G; Sherer F; Van Simaeys G; Goldman S; Ghanem G; Flamen P
    Mol Imaging Biol; 2015 Oct; 17(5):697-703. PubMed ID: 25761907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
    Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
    Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.